Knowing the Ethnic Specificity of Urinary Biomarker Proteins Could Refine Diagnosis of Lupus Nephritis
|
By LabMedica International staff writers Posted on 13 May 2020 |

Image: High magnification micrograph of diffuse proliferative lupus nephritis (Photo courtesy of Wikimedia Commons).
A study of biomarkers in the urine of African-Americans, Caucasian, and Asian patients suffering from lupus nephritis identified distinct patterns of proteins associated with each specific ethnicity, which may be useful in diagnosing the disorder.
Lupus nephritis (LN), one of the most severe complications of systemic lupus erythematosus (SLE), is a condition where the kidneys become inflamed and eventually lose function. It is estimated that approximately 60% of all SLE patients will develop LN, and in 10 to 15% of those patients the disease will progress to end-stage renal disease (ESRD). SLE and LN are both heavily influenced by genetics, and African-Americans are three times more likely to develop SLE than Caucasians.
The current gold standard for diagnosis of renal involvement is a renal biopsy. While biopsies are highly informative, they cannot be serially repeated and come with attendant concerns, including the invasive nature of the procedure, and the possibility that the sample taken may not be representative of the entire kidney.
Early detection and prompt treatment are known to have a significant impact on morbidity and mortality in LN, but current diagnostic techniques are not optimal for early detection. Therefore, an easily measurable biomarker for LN with high predictive value is highly desirable, and this has sparked significant research interest in this direction.
In this regard, investigators at the University of Houston (Texas, USA) screened urine samples from active LN patients for 1129 proteins using an aptamer-based platform, followed by ELISA validation in two independent cohorts comprised of 127 inactive lupus, 107 active LN, 67 active non-renal lupus patients and 74 healthy controls of three different ethnicities.
A commercially available, pre-fabricated aptamer-based-targeted proteomic assay was used for the study. In this assay, streptavidin-coated beads labeled with 1129 unique aptamers were added to each urine sample to allow them to bind to their designated protein targets. After incubation, the beads were removed from the sample, the proteins attached to the aptamers were biotinylated and all aptamer–protein complexes were cleaved from the initial streptavidin beads and re-coupled to a new bead, with the biotinylated protein attaching to the bead. The aptamers were then removed from the beads and quantitated using a DNA microarray.
Results revealed that the urine proteins that best distinguished active LN from inactive disease were ALCAM (activated leukocyte cell adhesion molecule), PF-4, properdin, and VCAM-1 (vascular cell adhesion molecule) among African-Americans; sE-selectin, VCAM-1, BFL-1 and hemopexin among Caucasians; and ALCAM, VCAM-1, TFPI and PF-4 among Asians. Most of these protein markers correlated significantly with disease activity indices in the respective ethnic groups, and surpassed conventional metrics in identifying active LN, with better sensitivity, and negative/positive predictive values. Several elevated urinary molecules were also expressed within the kidneys in LN, based on single-cell RNAseq analysis.
"While patient demographics are widely known to affect SLE disease manifestations and outcomes, there are virtually no studies investigating this phenomenon in the context of disease biomarkers," said senior author Dr. Chandra Mohan, professor of biomedical engineering at the University of Houston. "Most SLE biomarker studies focus on one demographic group or all ethnic groups combined, which yield results that may not be equally predictive in all demographic groups of SLE patients. Among African American patients, the most discriminatory biomarkers that distinguished active LN from inactive disease were urine ALCAM, PF-4, properdin, and VCAM-1. The best biomarkers lend themselves to be the best therapeutic targets because they tend to be disease drivers, and that is what is happening here with ALCAM."
The lupus nephritis study was published in the May 4, 2020, online edition of the journal Nature Communications.
Related Links:
University of Houston
Lupus nephritis (LN), one of the most severe complications of systemic lupus erythematosus (SLE), is a condition where the kidneys become inflamed and eventually lose function. It is estimated that approximately 60% of all SLE patients will develop LN, and in 10 to 15% of those patients the disease will progress to end-stage renal disease (ESRD). SLE and LN are both heavily influenced by genetics, and African-Americans are three times more likely to develop SLE than Caucasians.
The current gold standard for diagnosis of renal involvement is a renal biopsy. While biopsies are highly informative, they cannot be serially repeated and come with attendant concerns, including the invasive nature of the procedure, and the possibility that the sample taken may not be representative of the entire kidney.
Early detection and prompt treatment are known to have a significant impact on morbidity and mortality in LN, but current diagnostic techniques are not optimal for early detection. Therefore, an easily measurable biomarker for LN with high predictive value is highly desirable, and this has sparked significant research interest in this direction.
In this regard, investigators at the University of Houston (Texas, USA) screened urine samples from active LN patients for 1129 proteins using an aptamer-based platform, followed by ELISA validation in two independent cohorts comprised of 127 inactive lupus, 107 active LN, 67 active non-renal lupus patients and 74 healthy controls of three different ethnicities.
A commercially available, pre-fabricated aptamer-based-targeted proteomic assay was used for the study. In this assay, streptavidin-coated beads labeled with 1129 unique aptamers were added to each urine sample to allow them to bind to their designated protein targets. After incubation, the beads were removed from the sample, the proteins attached to the aptamers were biotinylated and all aptamer–protein complexes were cleaved from the initial streptavidin beads and re-coupled to a new bead, with the biotinylated protein attaching to the bead. The aptamers were then removed from the beads and quantitated using a DNA microarray.
Results revealed that the urine proteins that best distinguished active LN from inactive disease were ALCAM (activated leukocyte cell adhesion molecule), PF-4, properdin, and VCAM-1 (vascular cell adhesion molecule) among African-Americans; sE-selectin, VCAM-1, BFL-1 and hemopexin among Caucasians; and ALCAM, VCAM-1, TFPI and PF-4 among Asians. Most of these protein markers correlated significantly with disease activity indices in the respective ethnic groups, and surpassed conventional metrics in identifying active LN, with better sensitivity, and negative/positive predictive values. Several elevated urinary molecules were also expressed within the kidneys in LN, based on single-cell RNAseq analysis.
"While patient demographics are widely known to affect SLE disease manifestations and outcomes, there are virtually no studies investigating this phenomenon in the context of disease biomarkers," said senior author Dr. Chandra Mohan, professor of biomedical engineering at the University of Houston. "Most SLE biomarker studies focus on one demographic group or all ethnic groups combined, which yield results that may not be equally predictive in all demographic groups of SLE patients. Among African American patients, the most discriminatory biomarkers that distinguished active LN from inactive disease were urine ALCAM, PF-4, properdin, and VCAM-1. The best biomarkers lend themselves to be the best therapeutic targets because they tend to be disease drivers, and that is what is happening here with ALCAM."
The lupus nephritis study was published in the May 4, 2020, online edition of the journal Nature Communications.
Related Links:
University of Houston
Latest Molecular Diagnostics News
- Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
- Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
- Two-in-One DNA Analysis Improves Diagnostic Accuracy While Saving Time and Costs
- “Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
- New Tool Maps Chromosome Shifts in Cancer Cells to Predict Tumor Evolution
- Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
- Newly-Identified Parkinson’s Biomarkers to Enable Early Diagnosis Via Blood Tests
- New Blood Test Could Detect Pancreatic Cancer at More Treatable Stage
- Liquid Biopsy Could Replace Surgical Biopsy for Diagnosing Primary Central Nervous Lymphoma
- New Tool Reveals Hidden Metabolic Weakness in Blood Cancers
- World's First Blood Test Distinguishes Between Benign and Cancerous Lung Nodules
- Rapid Test Uses Mobile Phone to Identify Severe Imported Malaria Within Minutes
- Gut Microbiome Signatures Predict Long-Term Outcomes in Acute Pancreatitis
- Blood Test Promises Faster Answers for Deadly Fungal Infections
- Blood Test Could Detect Infection Exposure History
- Urine-Based MRD Test Tracks Response to Bladder Cancer Surgery
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







